Senescence in diffuse systemic sclerosis is elevated and may play a role in fibrosis.
作者信息
O'Reilly Steven
机构信息
Biosciences Department, Durham University, Durham, UK.
出版信息
Clin Exp Immunol. 2025 Jan 21;219(1). doi: 10.1093/cei/uxad077.
Abstract
摘要
相似文献
1
Senescence in diffuse systemic sclerosis is elevated and may play a role in fibrosis.弥漫性系统性硬化症中的衰老加剧，可能在纤维化过程中发挥作用。
Clin Exp Immunol. 2025 Jan 21;219(1). doi: 10.1093/cei/uxad077.
2
Dermal cellular senescence and EndMT in patients with systemic sclerosis undergoing cyclophosphamide or aHSCT treatment.接受环磷酰胺或自体造血干细胞移植治疗的系统性硬化症患者的皮肤细胞衰老和内皮-间质转化
Rheumatology (Oxford). 2025 Jun 1;64(6):3957-3963. doi: 10.1093/rheumatology/keae660.
3
Ferroptosis and Senescence: A Systematic Review.铁死亡与细胞衰老：一项系统综述
Int J Mol Sci. 2023 Feb 11;24(4):3658. doi: 10.3390/ijms24043658.
4
Critical Role for Transglutaminase 2 in Scleroderma Skin Fibrosis and in the Development of Dermal Sclerosis in a Mouse Model of Scleroderma.转谷氨酰胺酶2在硬皮病皮肤纤维化及硬皮病小鼠模型真皮硬化发展中的关键作用
Arthritis Rheumatol. 2025 Jul;77(7):914-928. doi: 10.1002/art.43104. Epub 2025 May 19.
5
Cyclophosphamide for connective tissue disease-associated interstitial lung disease.环磷酰胺用于治疗结缔组织病相关的间质性肺疾病。
Cochrane Database Syst Rev. 2018 Jan 3;1(1):CD010908. doi: 10.1002/14651858.CD010908.pub2.
6
Therapeutic management of fibrosis in systemic sclerosis patients - an analysis from the Swiss EUSTAR cohort.系统性硬皮病患者纤维化的治疗管理——来自瑞士 EUSTAR 队列的分析。
Swiss Med Wkly. 2024 Feb 6;154:3630. doi: 10.57187/s.3630.
7
Δ133p53α-mediated inhibition of astrocyte senescence and neurotoxicity as a possible therapeutic approach for neurodegenerative diseases.Δ133p53α介导的星形胶质细胞衰老和神经毒性抑制作为神经退行性疾病的一种可能治疗方法。
Neuroscience. 2025 Jun 14;580:54-61. doi: 10.1016/j.neuroscience.2025.06.031.
8
Prevalence, causes, and clinical associations of anemia in patients with systemic sclerosis: A cohort study.系统性硬化症患者贫血的患病率、病因及临床关联：一项队列研究。
J Scleroderma Relat Disord. 2024 Oct;9(3):203-209. doi: 10.1177/23971983241238921. Epub 2024 Mar 26.
9
Impact of Innovative Treatment Using Biological Drugs for the Modulation of Diffuse Cutaneous Systemic Sclerosis: A Systematic Review.生物药物治疗弥漫性皮肤系统性硬化症的影响：系统评价。
Medicina (Kaunas). 2023 Jan 27;59(2):247. doi: 10.3390/medicina59020247.
10
Intratympanic corticosteroids for sudden sensorineural hearing loss.鼓室内皮质类固醇治疗突发性聋。
Cochrane Database Syst Rev. 2022 Jul 22;7(7):CD008080. doi: 10.1002/14651858.CD008080.pub2.
引用本文的文献
1
Promoting ER stress in a plasmacytoid dendritic cell line drives fibroblast activation.在浆细胞样树突状细胞系中促进内质网应激会驱动成纤维细胞活化。
Cell Commun Signal. 2025 Feb 7;23(1):66. doi: 10.1186/s12964-025-02057-7.
2
Aging, senescence, and cutaneous wound healing-a complex relationship.衰老、衰老和皮肤伤口愈合——复杂的关系。
Front Immunol. 2024 Oct 17;15:1429716. doi: 10.3389/fimmu.2024.1429716. eCollection 2024.
3
Interleukin-11 and its eminent role in tissue fibrosis: a possible therapeutic target.白细胞介素-11 及其在组织纤维化中的重要作用：一个可能的治疗靶点。
Clin Exp Immunol. 2023 Dec 12;214(2):154-161. doi: 10.1093/cei/uxad108.
本文引用的文献
1
Inhibition of antiapoptotic BCL-2 proteins with ABT-263 induces fibroblast apoptosis, reversing persistent pulmonary fibrosis.ABT-263 通过抑制抗凋亡 BCL-2 蛋白诱导成纤维细胞凋亡，从而逆转持续性肺纤维化。
JCI Insight. 2023 Feb 8;8(3):e163762. doi: 10.1172/jci.insight.163762.
2
Senescent Cells Accumulate in Systemic Sclerosis Skin.衰老细胞在系统性硬化症皮肤中积累。
J Invest Dermatol. 2023 Apr;143(4):661-664.e5. doi: 10.1016/j.jid.2022.09.652. Epub 2022 Sep 30.
3
Genomic instability in early systemic sclerosis.早期系统性硬化症中的基因组不稳定性。
J Autoimmun. 2022 Jul;131:102847. doi: 10.1016/j.jaut.2022.102847. Epub 2022 Jul 6.
4
Evidence of telomere attrition and a potential role for DNA damage in systemic sclerosis.端粒损耗的证据以及DNA损伤在系统性硬化症中的潜在作用。
Immun Ageing. 2022 Jan 27;19(1):7. doi: 10.1186/s12979-022-00263-2.
5
Peripheral blood leucocyte telomere length is associated with progression of interstitial lung disease in systemic sclerosis.外周血白细胞端粒长度与系统性硬化症间质性肺病的进展相关。
Thorax. 2021 Dec;76(12):1186-1192. doi: 10.1136/thoraxjnl-2020-215918. Epub 2021 Jul 16.
6
Autoantibodies targeting telomere-associated proteins in systemic sclerosis.针对系统性硬化症中与端粒相关蛋白的自身抗体。
Ann Rheum Dis. 2021 Jul;80(7):912-919. doi: 10.1136/annrheumdis-2020-218918. Epub 2021 Jan 25.
7
Senescence Signature in Skin Biopsies From Systemic Sclerosis Patients Treated With Senolytic Therapy: Potential Predictor of Clinical Response?接受衰老细胞清除疗法的系统性硬化症患者皮肤活检中的衰老特征：临床反应的潜在预测指标？
Arthritis Rheumatol. 2019 Oct;71(10):1766-1767. doi: 10.1002/art.40934. Epub 2019 Sep 2.
8
Short lymphocyte, but not granulocyte, telomere length in a subset of patients with systemic sclerosis.系统性硬化症患者亚组中淋巴细胞端粒长度较短，但粒细胞端粒长度无此现象。
Ann Rheum Dis. 2019 Aug;78(8):1142-1144. doi: 10.1136/annrheumdis-2018-214499. Epub 2019 Jan 24.
9
Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study.特发性肺纤维化中的衰老细胞清除：首次人体、开放标签、先导研究的结果。
EBioMedicine. 2019 Feb;40:554-563. doi: 10.1016/j.ebiom.2018.12.052. Epub 2019 Jan 5.
10
The immunopathogenesis of fibrosis in systemic sclerosis.系统性硬化症中纤维化的免疫发病机制。
Clin Exp Immunol. 2019 Mar;195(3):310-321. doi: 10.1111/cei.13238. Epub 2018 Dec 10.
Zotero 插件